Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Non-metastatic NSCLC and other thoracic malignancies

5105 - Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial


11 Sep 2017


Non-metastatic NSCLC and other thoracic malignancies


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Non-Small Cell Lung Cancer


Jordi Remon Masip


Annals of Oncology (2017) 28 (suppl_5): v453-v456. 10.1093/annonc/mdx381


J. Remon Masip1, A. Martinez-Marti1, E. Carcereny Costa2, J. Zeron-Medina Cuairan1, I. Sansano3, J.L. Mate4, N. Pardo5, S. Cedres1, A. Navarro6, A.M. Martinez de castro5, T. Moran7, E. Felip Font8

Author affiliations

  • 1 Medical Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 2 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 3 Pathology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 4 Pathology, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES
  • 5 Medical Oncology, Vall d´Hebron University Hospital/Vall d´Hebron Institute Oncology, 08035 - Barcelona/ES
  • 6 Deparment Of Oncology, University Hospital Vall d’Hebron, 08035 - Barcelona/ES
  • 7 Medical Oncology, Hospital Universitari Germans Trias i Pujol, badalona/ES
  • 8 Medical Oncology Service (lung Cancer Unit)  , Vall d'Hebron University Hospital, 08035 - Barcelona/ES


Abstract 5105


Randomized phase III NATCH trial in early-stage non-small cell lung cancer (NSCLC) patients (p) reported no statistically differences in disease-free survival (DFS) or overall survival (OS) with the addition of preoperative or adjuvant chemotherapy to surgery. In pre-operative arm, those p who achieved a complete response obtained a benefit in 5-year DFS rate (59% vs. 38%). Recently, major pathological response (MPR) to preoperative chemotherapy (10% or less of residual viable tumor after preoperative therapy) has reported as surrogate marker of OS. The aim of this study is to validate MPR as prognostic factor in a cohort of patients included the NATCH trial.


MPR was analysed in a whole cohort of 57 early-stage NSCLC p treated in the preoperative arm into NATCH trial from 2 institutions. OS according to MPR was analysed (long-rank test) in the whole population and by histologic subtype.


In this cohort, median age was 67 years (47-78), 48 p (84%) were males, 26 p (46%) squamous subtype. By stage according to 6th TNM: 9 p (16%) stage IA, 35 p (61%) stage IB, 12 p (21%) stage IIB and 1 p (2%) stage IIIA. 95% p completed 3 cycles of preoperative treatment. Surgical procedures: 81% lobectomies, 14% pneumonectomies, 5% no surgery. 13 out of 57 p (22.8%) had MPR. In the whole population, there was an increase in 5-year OS among those patients with MPR compare to p without MPR (84.6% vs. 58.5%, p = 0.106). According to histological subtype, 5-year OS in squamous NSCLC p with MPR was significantly longer than in p without MPR (100% vs. 47.1%, p = 0.026), but not differences in OS in non-squamous were detected (66.7% vs. 66.7%, p = 0.586).


MPR is a prognostic value in squamous NSCLC p who receive preoperative chemotherapy. Validation in extended cohort merits further evaluation.

Clinical trial identification

Legal entity responsible for the study

Enriqueta Felip




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.